Predictive significance of an optimized panel for basal-like breast cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 phase III clinical trials

CONCLUSIONS: The nestin/INPP4B immunohistochemical panel identifies women with basal breast cancers who benefit from non-anthracycline chemotherapy but not endocrine adjuvant treatments.PMID:34615722 | DOI:10.1158/1078-0432.CCR-21-1942

Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Karama Asleh Dongsheng Tu Dongxia Gao Vivien Bramwell Mark N Levine Kathleen I Pritchard Lois E Shepherd Torsten O Nielsen Source Type: research